Equities Analysts Set Expectations for Precigen Q3 Earnings

Key Points

• HC Wainwright reiterated a Buy rating on Precigen and kept a $11 price target, while estimating Q3 2026 EPS of $0.01. The firm also projected steady earnings improvement through 2027.
• Precigen recently beat Q1 expectations, posting a loss of $(0.02) per share versus the expected $(0.03), and revenue of $23.25 million versus $20.81 million forecast. The better-than-expected results were supported by momentum in the company’s PAPZIMEOS launch.
• Wall Street sentiment is mixed overall, with analysts averaging a Hold rating despite several bullish calls and multiple institutional investors increasing their stakes. Notably, director Randal J. Kirk sold most of his shares in a large insider transaction.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - HC Wainwright issued their Q3 2026 EPS estimates for Precigen in a report issued on Thursday, May 14th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of $0.01 for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Precigen's current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Precigen's Q4 2026 earnings at $0.04 EPS, Q1 2027 earnings at $0.05 EPS, Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.09 EPS and Q4 2027 earnings at $0.12 EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The company had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%.

PGEN has been the topic of a number of other research reports. Zacks Research raised shares of Precigen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Citizens Jmp increased their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of Precigen in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Citigroup reissued an "outperform" rating on shares of Precigen in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $11.00.

Precigen Stock Performance

NASDAQ:PGEN opened at $4.42 on Monday. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The company has a market cap of $1.58 billion, a P/E ratio of -3.75 and a beta of 1.07. Precigen has a fifty-two week low of $1.28 and a fifty-two week high of $5.47. The firm's 50 day moving average is $3.85 and its two-hundred day moving average is $4.08.

Institutional Investors Weigh In On Precigen

A number of large investors have recently added to or reduced their stakes in PGEN. Patient Capital Management LLC grew its holdings in Precigen by 62.6% during the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company's stock valued at $87,056,000 after purchasing an additional 10,192,107 shares in the last quarter. State Street Corp grew its holdings in Precigen by 141.1% during the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company's stock valued at $45,248,000 after purchasing an additional 6,335,033 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in Precigen during the 4th quarter valued at $12,540,000. Bank of America Corp DE grew its holdings in Precigen by 201.1% during the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company's stock valued at $8,245,000 after purchasing an additional 1,673,731 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Precigen by 196.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company's stock valued at $9,087,000 after purchasing an additional 1,440,446 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Randal J. Kirk sold 4,772,781 shares of the firm's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $3.30, for a total transaction of $15,750,177.30. Following the completion of the sale, the director directly owned 302,213 shares of the company's stock, valued at approximately $997,302.90. This trade represents a 94.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 47.10% of the company's stock.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Precigen reported Q1 results that topped revenue expectations, with a smaller-than-expected loss per share, supporting the view that the business is executing better than anticipated. Article: Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
• Positive Sentiment: Management highlighted rapid PAPZIMEOS launch momentum on the earnings call, which appears to be driving investor enthusiasm around the company’s lead cancer therapy. Article: Precigen Earnings Call Highlights PAPZIMEOS Launch Surge
• Positive Sentiment: Citizens JMP raised its price target on Precigen to $11.00 from $9.00 and kept an outperform rating, signaling increased Wall Street confidence in the stock’s upside. Article: Precigen NASDAQ: PGEN Given New $11.00 Price Target at Citizens Jmp
• Neutral Sentiment: Several coverage items and transcript summaries recapped the Q1 call and stock move, but they did not add materially new information beyond the strong launch narrative already driving sentiment. Article: Precigen (PGEN) Q1 2026 Earnings Transcript
• Neutral Sentiment: Analyst-estimate and stock commentary pieces suggest traders are now focused on how quickly PAPZIMEOS revenue can scale and whether the company can approach cash-flow breakeven by the end of 2026. Article: Precigen anticipates funding through cash flow breakeven by end of 2026 as PAPZIMEOS launch scales

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.